Abstract:We previously demonstrated significant therapeutic activities associated with adenoviral vector-mediated Herpes Simplex Virus/thymidine kinase (AdHSV-tk) with ganciclovir (GCV) in situ gene therapy in the RM-1 orthotopic mouse prostate cancer model and interleukin-12 (AdmIL-12) in situ gene therapy in the RM-9 orthotopic mouse prostate model for prostate cancer. In both protocols, local cytotoxicity and activities against pre-established lung metastases were demonstrated. To test whether combined AdHSV-tk+GCV+IL-12 gene therapy would lead to enhanced therapeutic effects when compared to either treatment alone, we used RM-9 mouse prostate cancer cells in both orthotopic and pre-established lung metastases models of prostate cancer. Combined treatment with a single injection of optimal doses of AdHSV-tk+GCV or AdmIL-12 led to significantly increased suppression of orthotopic tumor growth. IL-12 gene therapy alone was more effective than AdHSV-tk+GCV in suppressing spontaneous lymph node metastases and pre-established lung metastases but combination gene therapy did not result in additional anti-metastatic activities. Combination gene therapy also did not achieve significantly better animal survival compared to AdHSV-tk+GCV or AdmIL-12 alone. Analysis of localized antitumor activities demonstrated that AdHSV-tk+GCV therapy induced higher levels of necrosis compared to AdmIL-12 or combination therapy. However, both treatments alone and combination therapy produced similar increases in apoptotic index. To address the possible mechanisms of locally co-operative cytotoxic activities, we analyzed the systemic natural killer (NK) response and the numbers of tumor-infiltrating immune cells using quantitative immunohistochemical analysis. AdHSV-tk+GCV therapy alone led to detectable increases in iNOS-positive cells, CD4+and CD8+T-cells and moderately increased numbers of F4/80 (macrophage selective)-positive cells within treated tumors. In contrast, AdmIL-12 elicited a highly robust pattern of tumor infiltration for all four of these immune cells that was in general mimicked by combination therapy. Further analysis of the accumulation of transforming growth factor-β1 (TGF-β1) immunohistochemical staining demonstrated that AdHSV-tk+GCV treatment, but not AdmIL-12 treatment, produced cancer cell-associated increases in this cytokine relative to control Ad-β-gal injections. Interestingly, local injection with AdHSV-tk+GCV induced significant splenocyte-derived NK cell cytolytic activities with maximal response 7 days following treatment, whereas AdmIL-12 injection produced significantly higher NK activity with maximal response 2 days following injection. The combined treatment produced a higher systemic NK response over the 14-day treatment period. Depletion of NK cells in vivo demonstrated that this immunocyte subpopulation was responsible for early locally cytotoxic activities induced by AdHSV-tk+GCV but not AdmIL-12 and that NK activities were largely responsible for activities against pre-established metastases generated by both gene therapy protocols.

Combined IL-12 and GM-CSF gene therapy for murine hepatocellular carcinoma

[Study on the Effects of Combined IL-12 and GM-CSF Gene Therapy for Murine Liver Cancer].

Combined IL-2 and IL-12 Gene Therapy for Murine Head and Neck Squamous Cell Carcinoma.

Gene Therapy in Vivo for Hepatocellular Carcinoma Using Double Suicide Genes Combined with IL-12 Gene

Combined Interleukin 12 and Interleukin 2 Gene Therapy for Hepatocellular Carcinoma in A Rat Model

Gene Therapy with Tumor-Specific Promoter Mediated Suicide Gene Plus IL-12 Gene Enhanced Tumor Inhibition and Prolonged Host Survival in a Murine Model of Lewis Lung Carcinoma

[Application of a Tumor Cell Vaccine Transfected with GM-CSF/IL-2 Fusion Gene for Specific Immunotherapy of Hepatocellular Carcinoma].

[Therapeutic effect of cationic liposome-mediated interleukin-12 gene delivery on murine melanoma in vivo].

Effects of gamma-interferon gene-modified hepatocytes on murine implanted liver carcinoma

Studies on the Effects of Combined IL-12 and CD40L Gene Therapy for Murine Melanoma

Tumor‐Associated Macrophage and Tumor‐Cell Dually Transfecting Polyplexes for Efficient Interleukin‐12 Cancer Gene Therapy

Combination Nonviral Murine Interleukin 2 And Interleukin 12 Gene Therapy And Radiotherapy For Head And Neck Squamous Cell Carcinoma

Antitumor Effects Of Interleukin-18 Gene-Modified Hepatocyte Cell Line On Implanted Liver Carcinoma

The Adoptive Theraputic Effect of Interleukin-12 Gene Transfected Splenocytes from the Mice Immunized by Immunogene Tumor Vaccine on Implanted Liver Cancer

Combination Radiation and Gene Therapy for Head and Neck Squamous Cell Carcinoma in the Murine Model

[Treatment of Hepatocellular Carcinoma by Transfecting Interleukin-12 and Interleukin-2 Fusion Gene Intrasplenically, an Experimental Study].

Effects of recombinant murine interlukin-12 and GM-CSF gene adenovirus vectors on B16 melanoma

Pharmacokinetics of Combined Gene Therapy Expressing Constitutive Human GM-CSF and Hyperthermia-Regulated Human IL-12.

[Combined Interleukin-2 and Herpes Simplex Virus Thymidine Kinase Gene Therapy for Head and Neck Squamous Cell Carcinoma].

Local and Systemic Delivery of Interleukin-12 Gene by Cationic Micelles for Cancer Immunogene Therapy.

Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer